

The Prostate Cancer Foundation (PCF) and Pfizer Inc.
Independent Medical Education
Implementing Germline and Somatic Testing
for Precision Medicine in Community-Based
Prostate Cancer Care
Visiting Professorship Program Additional Information

I. Background

About the Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has raised more than \$1 billion to fund cutting-edge research through more than 2,615 research projects at 312 leading cancer centers, with a global footprint spanning 29 countries. Since PCF's inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. PCF is committed to the mission of ending death and suffering from this disease. Learn more at pcf.org.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies. Pfizer's GMG competitive grant program involves a publicly posted request for proposals (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses a scientific review committee (SRC) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in practice or care as outlined in the specific RFP.

About this Visiting Professorship (VP) Program

This program is to provide financial support to community-based urology and medical oncology Organizations (e.g., independent community urology practices governed by a Board of Directors, community-based medical oncology groups, hospital-affiliated community cancer centers) to host and coordinate a 2.5-to-3 hour medical education program to be led by 1-2 Visiting Professors whose expertise matches the Organization's unmet educational and practice needs related to germline/genetic and somatic (tumor and/or ctDNA) testing for patients with prostate cancer, such as:

- Understanding the science of these tests and clinical applications of testing
- Patient selection (whom to test and when)
- Communicating benefits of testing, risks and results and implications to patients and families
- Effective strategies to integrate testing into clinical workflows, such as enabling advanced practice

providers to provide support and/or incorporating novel digital tools that support clinical decision-making

- Addressing and overcoming financial and reimbursement barriers to testing

Targeting these gaps, the goals of this first-time competitive Visiting Professor program are to provide meaningful education for prostate cancer care teams in community practice, building capacity by helping them identify gaps in patient care, helping engineer practice-level solutions, and fostering collaborations among community-based practitioners and academic experts. Urologists, medical oncologists, advanced practice providers, and patients will benefit from the knowledge and onsite presence of distinguished clinical experts who might otherwise be inaccessible.

The goal of this program is to help initiate/ implement a practice level-solution to improve the delivery of prostate cancer care at the grantee's site specific to their unique practice gaps related to germline and somatic testing. Our support for this program reflects our commitment to improving outcomes for patients with prostate cancer and advancing clinical expertise, education, and capacity for healthcare professionals.

II. Eligibility

Geographic Scope:	United States Only
Institutions Eligibility Criteria:	• Applicant must have a medical degree (MD, DO, MBBS, NP or equivalent,) and hold a position as a urologist or medical oncologist seeing patients with prostate cancer. • Applicant must be an employee or independent contractor of the requesting Organization. • The requesting Organization must be a urology and/or medical oncology Organization providing care for patients with prostate cancer. • Applicant should serve as Chair of the proposed medical education program and play a lead role in implementation. • Only community-based urology or medical oncology practices (Organizations) are eligible to receive Grants. • Organization and hosting team must be in the United States. • The education program may involve participants from multiple clinical specialties or service areas within the Organization as long as all participants have a relevant role and educational need. • Organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this prior to applying. Grants approved to organizations that are subsequently determined to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

III. Details and Requirements

Date Issued:	April 21, 2026 - reissued August 7, 2026
Clinical Area:	Urology and Oncology – Genitourinary – Prostate Cancer
Area of Interest:	The intent of this Request for Proposals (RFP) is to invite Organizations to submit applications to host a 2.5-to-3 hour medical education program at or nearby the Organization, led by 1-2 Visiting Professors (VPs) with expertise matched to the Organization's unmet educational and pragmatic needs related to germline and somatic (tumor and/or ctDNA) testing for patients with prostate cancer. After the education program, Organizations will implement projects to incorporate, increase, or improve the use of guideline-concordant testing to improve prostate cancer patient care.
Application Requirements:	Complete and submit the Application Template. Applications from Organizations interested in this program should include, but are not limited to, the following information: • Description of the Organization's impact, and reach. This includes statistics and descriptions of the following: • Organization's name and size of service area/location • Estimated number of prostate cancer patients served • Estimated percentage of patients with prostate cancer referred for somatic and germline testing. • If known, Organizations may also include estimates on/of: ▪ Any underserved or high-risk patient populations seen. ▪ Total and individual numbers of clinical staff providing prostate cancer care i.e. urologists, medical oncologists, APPs, nurses, navigators, genetic counselors, etc. ▪ Any involvement in clinical trials. ▪ Any prostate cancer educational platforms or programs. • Description of the Organization's gaps, unmet needs, challenges, and questions on providing and using germline and somatic testing for the management of patients with prostate cancer for which a Visiting Professor could provide education or assistance, <u>such as</u>: • Training needs of healthcare team, including physicians, nurses, and other allied health professionals. ▪ May include but is not limited to the following: core concepts and clinical applications for testing, patient

	selection, use of results for prognostication, management / treatment selection, clinical trial referrals, communicating about tests and results with patients and families. • Gaps or challenges related to integrating tests into clinical workflows, any solutions attempted to date, impact and any planned improvements. • Prostate cancer care disparities that the program can impact. • Support needs related to addressing costs of these tests, insurance/payers, etc. • Skills and knowledge needs and program format for a 2.5-to-3-hour medical education program covering a concise clinical review, discussion of practice-specific gaps, and solutions to address these gaps. The program can include but is not limited to: • Description of desired expertise you would like your Visiting Professor(s) to be able to share with your practice. • Proposed topics to be covered. The VP and awardee can work together to create the program agenda once the VP is assigned to the site. • Information (if any) you would like the VP to review, including but not limited to: workflows, processes, staffing • Expected number of healthcare professionals attending this Program. • Outcomes measurement: Please include 1-2 quantifiable outcome metrics related to the project goal(s), to be discussed and confirmed during the education program and included in a concise outcomes report submitted by the Organization 6 and 12 months after the program (e.g. a baseline to current / post-program comparison). Please see Application Template for examples of metrics and what to include. Note: Your 6 and 12-month outcome reports may also include but are not limited to: • Changes in patient management and outcomes • Impact on healthcare provider knowledge and/or patient understanding related to unmet needs • Resulting practice changes, and the sustainability of those changes • Potential replicability • Collaborations with or dissemination to other oncology sites, medical groups, etc.
--	---

	• Availability / interest in participating in PCF Scientific Retreat. In 2027, PCF will provide registration and travel support for one participant per Organization to attend the PCF Scientific Retreat, the world's foremost scientific conference on prostate cancer biology and treatment, which is held annually in autumn. Please indicate Organization's interest and expected availability to attend. • Availability and willingness to participate in video interviews. After the program, PCF will create videos in which participants describe their Organization's baseline somatic and germline genetic testing challenges, learnings, practice-specific solutions, and concrete outcomes. These videos help disseminate key learnings to a wider clinical audience and will be hosted publicly on UroToday. Please indicate your interest and willingness to participate in a video interview, either onsite at PCF Scientific Retreat or virtually. • Letter of Support from Organization Leadership: When emailing your application to akaron@pcf.org and lori.carpenter@pfizer.com please attach a brief letter of support from your Practice Manager, Practice Administrator, Medical Director, CEO, President, Managing Partner, or equivalent that a) confirms your Organization's support for hosting the Visiting Professor and onsite program and b) implementing the small process improvement project afterward. • In the Application Template or attached separately, provide a line-item budget for all local costs of implementing the germline and somatic testing project at the healthcare site, such as costs of local onsite management, logistics, staff time, planning, and other implementation, initiation, or metrics tracking costs. PLEASE NOTE: PCF will <u>SEPARATELY</u> cover expenses for the onsite Visiting Professor visit such as meeting room rental if required, a meal, AV, and travel expenses and honoraria for Visiting Professors; therefore, please DO NOT include these costs in the line-item budget.
Target Audience:	A urologist or medical oncologist should serve as Program Chair, but clinicians from all other medical disciplines can be included in the program plan, such as pathologists, APPs, nurses, navigators, other allied prostate cancer healthcare providers, genetic counselors, etc.
Expected Approximate Monetary Range of Grant Applications:	• The total budget for this program is \$250,000 USD, with plans to support 5-7 organizations. Individual project budgets should not exceed \$50,000 USD. • Please note: PCF will select 1-2 Visiting Professors based on the approved program and its knowledge gaps. Offsite or onsite physical meeting expenses including room, meals and AV as well

	as travel expenses and honoraria for Visiting Professors, will be covered separately and are not part of this Grant budget. - Approximately five to seven sites (5-7) will be supported by this educational program. - Applications will be reviewed by a scientific review committee (SRC). - The amount of the award will depend upon SRC's evaluation of proposal and costs involved and will be stated clearly in the award agreement.
How to Apply	Complete and submit the Application Template. Additional information on how to complete the template can be found on the template itself as well as in the Appendix below (pages 7 and 8 of this document).
Key Dates:	- Application release date: April 21, 2026 - Re-issued Aug 2026 with accompanying simplified Application Template for Organizations to fill out. - Application due Sept 9, 2026. Please note the deadline is 23:59 Eastern Time (New York, GMT -5). Applications submitted after deadline will not be reviewed. - Review of applications by SRC: September 2026 - Anticipated Grant Award Notification Date: Oct 2026 Grants will be distributed following a fully executed agreement. - Suggested Project Start and End Dates: November 1, 2026, to May 1, 2027.
Questions:	If you have questions regarding the Application Template or this RFP, please email Ari Karon (akaron@pcf.org).
Grant Agreements:	- If your Grant application is approved, your Organization will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement. - Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety. - Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application. - Except where prohibited by applicable local laws or regulations and, in any case, subject to review by Pfizer Legal, payment of grant

	funding may only be paid to the grantee organization in its country of domicile. • This grant is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.
Review and Approval Process:	• Grant requests received in response to a specific RFP are reviewed by a scientific review committee (SRC) to make final grant decisions. • The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement. • If approved, the grant seeker will be required to log in to the Pfizer portal for payment processing and reporting status.
Mechanism by which Applicants will be Notified:	• All applicants will be notified via email by the timeframe noted above. • Applicants may be asked for additional clarification during the review period.

Appendix

Application Submission Requirements

- **Gaps, Questions, Training Needs** Describe your Organization's gaps, unmet needs, and questions related to germline and somatic testing that a Visiting Professor could address, including any team training needs and, if relevant, care disparities this program could impact.
- **Skills and Knowledge Needs and Program Format**
Describe the clinical, workflow-related, or other skills and knowledge you would like your Visiting Professor to have to address your gaps and unmet needs; the education format(s) you would prefer during your onsite program, such as lectures, patient case reviews, workflow reviews, and informal discussions; and approximately how many healthcare professionals you expect to attend.
- **Outcomes Measurement**
In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Specify 1-2 quantifiable Program outcomes you plan to track and report for your organization at 6 and 12 months. List the data sources your organization currently expects to use to assess these outcomes.
- **Participation in PCF Scientific Retreat**
We will provide travel and registration support for one participant per awarded Organization to attend the 2027 PCF Scientific Retreat, an invitation-only meeting that is the foremost scientific conference in the world on the biology and treatment of prostate cancer. The Retreat is held annually in autumn (October 2027). Please indicate interest and willingness for a clinician from your Organization to attend.

- **Participation in Video Interviews**

After the program, we will create short videos in which participants describe their baseline testing challenges, learnings, practice-specific solutions, and outcomes. These videos will be hosted publicly on UroToday. Please indicate your interest and willingness to participate.

- **Budget Detail**

While estimating your budget, please keep the following in mind:

- Your budget should not exceed \$50,000.
- Please **DO NOT INCLUDE** any costs related to Visiting Professor travel, VP honoraria, room rental for onsite half-day VP program, AV for onsite VP half-day program, or other onsite facilities costs for the onsite program. PCF will cover these costs separately.
- Independent Medical Education Grants and Visiting Professorships awarded by GMG **cannot** be used to purchase therapeutic assets (prescription or non-prescription).
- **Pfizer may support up to 28% of overhead costs associated with the total proposed project budget. Please [click here](#) for details.** To be considered for support, general organizational running (i.e., overhead) costs such as legal fees, insurance, heating and lighting etc. should be included in an Institutional Overhead (if required). Most overhead/running costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, overhead/running costs that are specific to the project or study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.

- **Additional Information**

If there is any additional information you feel Pfizer should be aware of concerning the importance of this project for your Organization, please summarize in the relevant field in the Application Template.